GlobalData has released its pharma report, “PharmaPoint: Asthma – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies shaping and driving the global Asthma market. The report provides insight into the competitive Asthma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
Complete report available @ http://www.rnrmarketresearch.com/pharmapoint-asthma-current-and-future-players-market-report.html .
- - Investigation of current and future market competition for Asthma
- - Competitor assessment
- - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- - Strategic assessment of Asthma sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- - Gain a high level view of the trends shaping and driving Asthma market
- - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- - Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- - What’s the next big thing in the global Asthma market landscape? Identify, understand and capitalize
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=214290 .
List of Tables
Table 1: Global Sales Forecast ($m) for Asthma, 2013-2023 14
Table 2: Global Asthma Market - Drivers and Barriers, 2014 18
Table 3: Key Companies in the Asthma Market, 2014 22
Table 4: GSK's Asthma Portfolio Assessment, 2014 26
Table 5: GSK SWOT Analysis, 2013 27
Table 6: Merck's Asthma Portfolio Assessment, 2014 29
Table 7: Merck SWOT Analysis, 2012 29
Table 8: AstraZeneca's Portfolio Assessment, 2014 31
Table 9: AstraZeneca SWOT Analysis, 2014 32
Table 10: Novartis' Asthma Portfolio Assessment, 2014 34
Table 11: Novartis SWOT Analysis, 2012 35
Table 12: Roche/Genentech's Portfolio Assessment, 2014 36
Table 13: Roche/Genentech SWOT Analysis, 2014 37
Table 14: Teva's Portfolio Assessment, 2014 39
Table 15: Teva SWOT Analysis, 2014 40
Table 16: Boehringer Ingelheim's Portfolio Assessment, 2014 42
Table 17: Boehringer Ingelheim SWOT Analysis, 2014 42
Table 18: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 51